NCT03344211View on ClinicalTrials.gov

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

November 21, 2026

Study Completion Date

November 21, 2027

Conditions
Castration-Resistant Prostate CarcinomaProstate Carcinoma Metastatic in the BoneStage IV Prostate Cancer
Interventions
DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Radium Ra 223 Dichloride

Given IV

Trial Locations (3)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

91010

City of Hope, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT03344211 - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter